Checkpoint Therapeutics Inc’s Post

In regulatory affairs news, Checkpoint Therapeutics Inc announced it has reached alignment with the Food and Drug Administration on its biologics license application (BLA) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Cosibelimab is a human IgG1 monoclonal antibody that directly binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with the PD-1 and B7.1 receptors. https://lnkd.in/eydHXwXx

Aprea Therapeutics begins patient dosing in ACESOT-1051 phase 1 trial evaluating oral WEE1 inhibitor APR-1051

📢 Check out this #HighlyCitedPaper by Marques et al: "Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy" 🎯 💊 👇 You can find it at: https://lnkd.in/g8Qff-mX

𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 (𝗧𝗥𝗧) represent an area of growing investment by the pharmaceutical industry. This blog explains how using clinical pharmacology best practices can refine TRT dose selection and enhance treatment outcomes. Read our latest insights:  https://ow.ly/5C4p50QZ5OB #CancerResearch #TargetedRadiationTherapy #CancerTreatment #Oncology #ClinicalTrials #FDAguidelines #EMAguidelines #ProjectOptimus #ModelingSimulation #PKdata #DoseSelection #ClinicalPharmacology

From the clinical data of Mersana Therapeutics' two anti-NaPi2b ADCs (XMT-1536, XMT-1592), we can learn that 'linker stability' can sometimes be more detrimental than beneficial, depending on the target. https://lnkd.in/gMbVi_H5

Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor - Breakpoint’s polymerase theta inhibitor development candidate, a potent and selective small molecule, was nominated based on its best-in-class potential to treat cancers with defined defects in DDR pathways - Excellent profile of Breakpoint’s polymerase theta inhibitor provides mechanistic synergy and huge optionality for clinical combination with various other agents, including targeted drugs such as PARP inhibitors, chemo- and radiation therapy, radioligand therapy (RLT) and ADCs - Candidate molecule originated from integrated drug discovery efforts performed in alliance with Evotec See the press release here: https://lnkd.in/eqDqx6cn

Coming off a $50 million series B financing round, radiopharmaceutical developer Ratio Therapeutics has expanded its partnership with Florida-based CDMO PharmaLogic. About Ratio’s Technology Platforms Ratio Therapeutics’ fully integrated proprietary R&D platforms, Trillium™ and Macropa™, harness the tumor-killing power of the alpha emitting radionuclide actinium-225 to selectively destroy cancer cells. Trillium™ technology is a proprietary and innovative platform that incorporates a tunable, structural motif enabling our compounds to reversibly bind to albumin, thereby modulating their pharmacokinetics (PK) and improving drug availability, tumor delivery, and tumor loading, while simultaneously reducing the side effects commonly observed with other radiotherapies.   Ratio’s Macropa™ technology reflects a proprietary chelator that is used to attach the alpha emitting radionuclide actinium-225 to Trillium™ and other compounds. Its unique chemistry enables ease of manufacture and improves in vivo stability of the resulting compound. The news: https://lnkd.in/gGtQ9sen Ratio therapeutics: https://lnkd.in/gMuBGxPR

#radiopharmaceuticals are having a resurgence, partly due to the emergence of #targetedalphatherapies (#TATs). A key advantage of TATs is the short emission range and radiation concentration within a few cell diameters key. In this Q&A with European Pharmaceutical Review, Julien Dodet, CEO of Orano Med discusses trends in #radioligand therapeutics and why TATs hold significant advantages as #cancertreatment. https://lnkd.in/eGJxavWd

Optogenetics is SO cool - its agnostic therapies for all!

Thoughts on this? >> Artiva sets out $135M IPO plans to push NK cell therapy through trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #competitivemarketing #pharmaceutical #healthcare